

21ST ANNUAL FDA AND THE CHANGING PARADIGM FOR HCT/P REGULATION

April 13 – 15, 2026
Tysons Corner, Virginia
Hyatt Regency Tysons Corner Center

**REGISTER
NOW!**

Conference
presented by



*The top producer
of premier
pharmaceutical
conferences since 1995*

Presented in
cooperation with



About the Conference

Please join us in Tysons Corner, Virginia, for the **21st Annual FDA and the Changing Paradigm for HCT/P Regulation** conference. We are pleased to have representation from FDA and many industry experts crossing the broad spectrum of tissues, including ocular and reproductive, cells, and cellular and tissue-based products.

We will open the conference with a Recipient Story to remind all of us how important our work is to those recipients that receive tissues, cells, and cellular and tissue-based products.

FDA CBER has been confirmed to share the most current information with the Division of Human Tissues (DHT) update. Laurissa Flowers, Biologics National Expert from FDA's Office of Inspections and Investigations, is confirmed to give a presentation on the Inspectional Process and Most Frequently Cited Observations.

As the HCT/P landscape evolves and churns at FDA, coupled with anticipated changes for participants to keep on their radar, Politico's AgencyIQ will present on the state of the industry, providing an overview of key updates, developments and trends that are shaping today's HCT/P industry. Then we will delve into artificial intelligence and machine learning with a plenary talk on its use in donor screening and an interactive workshop on integrating AI into your Quality Systems to increase efficiencies, prevent hallucinations and maintain compliance. Former FDA, Dr. Carolyn Yong, will discuss case studies for wound care HCT/P products, as she considers regulatory expectations for each pathway or type of product, including testing strategies and quality/compliance expectations. And you do not want to miss the interesting discussions that occur during the Regulatory Jeopardy session!

Industry will provide insights on determining your product classification and finding the fastest route to FDA approval, plus a session on screening. Also, we will delve into the confounding process of screening for sepsis and associated 483s in a post-Mtb transmissions environment. In that same vein, we will cover microbiological testing for Mtb (Mycobacterium) addressing challenges and considerations for test method validation and limitations of rRNA testing for Mtb in recipients using laboratory developed tests. We will consider warning letters and what they are telling us about how FDA's current thinking is evolving and where enforcement is going.

The conference format again includes smaller workshops each afternoon that will allow participants to participate in an interactive format with industry experts. These include strengthening practices, preventing errors, and preparing for FDA audits in regard to donor eligibility and screening; HCT/P deviation reporting; looking at individual donor assessment and moving toward risk-based screening; and looking at lessons learned and considerations for implementation and execution of electronic batch production records, including demonstrations from an electronic system currently in use. Additionally included is a session on identifying a standard process for implementing commercially available HCT/Ps within an organization, specifically cell therapy products (e.g., CAR-T, genetically modified, etc.) that have been approved for commercial use by the FDA. We will again have a workshop specifically focused for the reproductive tissue industry on donor eligibility, accompanying records and labeling requirements led by industry (and closely organized with FDA). You can expect to learn as well as provide others with your own experiences and expertise during these sessions.

On the last day of the two-and-a-half-day conference, we will conclude with the ever popular "Ask the FDA" session. Send your questions early, even right after you register, to registration@pharmaconference.com (due by March 16, 2026). Be sure to meet and visit with FDA representatives at the meeting.

Register early to save hundreds of \$\$ and ensure your participation in a great learning opportunity and the chance to network with experts in your field both from industry and the FDA.

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

Who Should Attend?

- CEOs & COOs
- MDs and Medical Directors
- Donor Screeners
- Regulatory Managers and Personnel
- Recovery Personnel
- Quality Assurance Managers and Personnel
- Laboratory Supervisors and Personnel
- Processing Managers
- Compliance Professionals
- Legal Representation

Why Attend?

- Listen to FDA office and division updates
- Hear recent changes to the HCT/P landscape, as well as anticipated future updates you want to keep on your radar
- Screening for sepsis and associated 483s
- Learn about regulatory expectations for each pathway for HCT/Ps for Wounds
- Gain insight from OII on the Inspectional Process and Most Frequently Cited Observations
- Learn about the applications for artificial intelligence and machine learning in the HCT/P industry during a plenary session and interactive workshop
- Consider warning letters and what they are telling us about how FDA's current thinking is evolving and where enforcement actions are trending
- Discuss microbiological testing for Mtb (Mycobacterium) and the pitfalls and challenges of rRNA testing for Mtb in surgical site infections using laboratory developed tests
- Get training in strengthening practices, preventing errors, and preparing for FDA audits in regard to donor eligibility and screening
- Participate in interactive workshops on HCT/P deviation reporting and looking at individual donor assessments and moving toward risk-based screening
- Discuss Reproductive HCT/P specific issues related to Donor Eligibility, Accompanying Records and Labeling
- Look at FDA's evolving approach to donor screening, shifting from blanket deferrals to individualized, risk-based assessments
- Gain insight on determining your product classification and finding the fastest route to FDA approval
- And you do not want to miss the interesting discussions that occur during the Regulatory Jeopardy session!
- Interface with Industry experts and FDA

**What attendees
say about
FDA and the Changing
Paradigm for HCT/P
Regulation**

"Great topics discussed!"

"Overall, great conference in this very volatile regulatory time."

"The Jeopardy game was great – it opened the floor for great conversation."

"I enjoyed the workshop sessions on HCT/Ps."

**"First time coming and really appreciated the content and the people.
I've definitely taken more information and tools away!"**

About the Speakers



Erica Agy, BS – Ms. Agy has worked at Fred Hutchinson Cancer Center for the past 15 years and currently serves as the Interim Director of Quality Assurance. She is responsible for the regulatory and accreditation continuous readiness programs, managing inspection preparation, coordination, performance, and follow-up for FDA, FACT, CAP, TJC, as well as clinical trial sponsor audits and monitor visits for the Cellular Therapy Laboratory and the Apheresis Unit. Ms. Agy also oversees the QA/QC groups who support the GMP Cellular Processing Facility, the Clinical Labs Quality Assurance team, and the FACT Clinical Quality team at Fred Hutch.



Sally Alrabaa, MD – Dr. Alrabaa is a professor of infectious disease and international medicine with the department of internal medicine at the University of South Florida College of Medicine. She is the Tuberculosis Consult to the Pinellas Department of Health in Florida, overseeing treatment and prevention of Tuberculosis. Dr. Alrabaa is a donor and tissue eligibility consultant to multiple tissue processors and a contributor to the American Association of Tissue Banks (AATB), drafting guidelines regarding donor eligibility. She contributed to updating AATB standards in reducing tissue transmission of mycobacteria tuberculosis bacteria. Dr Alrabaa currently serves as the chair of AATB physician council.



Fatima Amchich, BS, MPH – Ms. Amchich is a Senior Regulatory Compliance Specialist at NMDP, specializing in the reviewing domestic and international donor and cord blood unit eligibility in accordance with regulatory and accreditation requirements. Her work focuses on ensuring accurate and consistent donor eligibility documentation that supports patient safety, regulatory compliance, and audit readiness. Ms. Amchich actively contributes to continuous improvement initiatives by identifying trends, gaps in eligibility review processes and collaborating on corrective and preventive actions that strengthen quality systems and reduce recurrence.



Jonathan Boyd, MS – Mr. Boyd's career in donation started in 2009 at an organ and tissue procurement organization, where he worked in surgical recovery and leadership roles. In 2017, he joined the Association for Advancing Tissue and Biologics and served as Director of Education until he moved to Lonza in 2023, where he is now the Director of Tissue Acquisition, leading a team supporting initiatives involving donated tissues and cells. Additionally, Mr. Boyd is the CEO of AlloEd, which offers technical training and education to donation and transplant professionals.



Rebecca Brown, MS, PhD – Dr. Brown is the founder of CGC, and her three decades of global experience encompass strategic leadership, regulatory expertise, quality oversight, and product innovation in biotechnology. She holds numerous patents, was named a Top 25 Women Leader in Medical Devices (2021), and collaborates with industry, regulatory bodies, and other organizations worldwide. Dr. Brown serves on Georgia Tech's College of Engineering Advisory Board and previously chaired its Mechanical Engineering Advisory Board and the Women of Woodruff program. She earned her SB from MIT and MS/PhD from Georgia Tech in Mechanical Engineering.



Chris Dayton, BS – Mr. Dayton is the Co-Founder and CEO of QualityAssured.ai, a company delivering closed-system, on-premise AI purpose-built for pharmaceutical and HCT/P quality operations. He specializes in applying AI to QMS, QRM, and regulated workflows while aligning with FDA, EMA, and MHRA expectations. Mr. Dayton advises life-science organizations on integrating inspection-ready AI, supports federal R&D initiatives, and speaks nationally on safe, compliant AI adoption in highly regulated manufacturing environments.



Jennifer DeMatteo, BS, MCM, CIC – Ms. DeMatteo is the Director of Regulations and Standards for the Eye Bank Association of America (EBAA). She oversees the EBAA Accreditation program, Medical Standards process and serves as their regulatory liaison. She was responsible for directing the Infection Prevention and Control (IPC) and Employee Health programs and personnel at major tertiary hospital and ambulatory care settings. Ms. DeMatteo has been a Healthcare Epidemiologist for over 20 years and is certified in Infection Control & Epidemiology (CBIC).



Wayne Dietz, CEBT – Mr. Dietz is the former Quality Assurance Director at the San Diego Eye Bank (SDEB). He recently transitioned to the position of Director of Community Outreach after celebrating his 40th anniversary at SDEB.

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

About the Speakers



Laurissa Flowers, BS – Ms. Flowers has served with the FDA for more than 14 years as a biologic's investigator, Biologics Specialist, and Supervisory Investigator, and now serves as a Biologics National Expert within the Office of Biologics Inspectorate (OBI). She has conducted hundreds of inspections and investigations in biologics, human tissue, biological drugs. Prior to joining the FDA Ms. Flowers served in the US Army as a Preventive Medicine Specialist, after which she attended and graduated from the University of Maryland, College Park with a degree in Kinesiology.



Alexander Gaffney, MS, RAC – Mr. Gaffney is a regulatory and media executive responsible for founding and leading the research division of AgencyIQ, the regulatory analysis division of the media company POLITICO. As the Vice President of Regulatory Policy and Intelligence, he directs the division's analysis of regulatory issues affecting pharmaceutical, biotechnology, medical device, and chemical companies. Before joining AgencyIQ, Mr. Gaffney analyzed life sciences regulations as part of PricewaterhouseCoopers's Health Research Institute and was the Manager of Regulatory Intelligence at the Regulatory Affairs Professionals Society (RAPS), where he also served as Managing Editor for the company's flagship publication, Regulatory Focus.



Ping He, MD – Dr. He is the Staff Chief of the Human Tissue and Reproduction Staff in the Division of Human Tissues within the Office of Cellular Therapy and Human Tissue, in the Office of Therapeutic Products, CBER. She coordinates the review and analysis of medical and scientific information and regulatory submissions related to HCT/P safety and compliance. Dr. He leads a team responsible for developing regulatory policies, supporting compliance activities, and addressing manufacturer and public inquires and exemption requests.



Sangita Jindal, PhD, HCLD – Dr. Jindal earned her PhD in Physiology from the University of Toronto, Canada. For the last 23 years she has been on the faculty at Albert Einstein College of Medicine in New York as Professor and IVF Laboratory Director in the Department of Obstetrics, Gynecology & Women's Health. She is also an off-site lab director of private and academic IVF laboratories across the country. Dr. Jindal serves in leadership roles nationally and internationally within the field of clinical reproductive science.



Amy B. Johnson – Ms. Johnson is the Associate Director of Tissue Services at Eversana. As a quality and regulatory specialist with more than 20 years of experience with human tissue requirements, she has an extensive background in regulatory body enforcement responses and remediation activities, Quality Management Systems, auditing, and training. She enjoys working with tissue establishments to help them achieve and maintain compliance with applicable FDA, state, and other regulatory body requirements.



Alyce Linthurst Jones, PhD – Dr. Linthurst Jones is the Scientific Liaison and Quality Vice President at LifeNet Health. Over the last 30 years, she has cultivated a breadth and depth of scientific, regulatory, clinical, research, and product development knowledge directly applicable to the realization of novel tissue-based products and medical devices for cardiac, vascular, orthopedic, and trauma applications. Dr. Linthurst Jones has developed and brought several novel tissue-based medical devices through the US FDA through numerous on-site presentations and authoring multiple submissions [IDE (inclusive of clinical trial), pre-RFD, RFDs, Qsubs, (clinical and pre-clinical), ESRD Innovation Pathway and multiple 510(k)s] and has also supported regulatory submissions to numerous countries where tissue-based products are regulated as drugs. She has various publications and book chapters in the field of cardiovascular tissue engineering, tissue disinfection, and processing as well as multiple patents. Dr. Linthurst Jones is active in ASTM F04.44 for Tissue Engineered Medical Products (TEMPS) and AATB Scientific and Technical Affairs and Standards Committees.



Katie Laney, BS – Ms. Laney is the owner and founder of Solaris SRB. She is a Quality and Regulatory professional with over 20 years of experience in the Life Sciences industry and has a proven track record of providing solutions-oriented advisement to guide product development and commercialization efforts for a vast portfolio of advanced therapeutic products. With niche experience in the evolving regulatory landscape for HCT/PS, Ms. Laney has led the charge in innovative FDA regulatory activity, including authoring of numerous pre-IND, IND and BLA submissions, as well as successful requests for 1271 exemptions.



Charles "Cheyne" Levermore, BAsC, MIB, MDA – Mr. Levermore has over 20 years of leadership experience across healthcare and medical device organizations. He specializes in analytics driven strategy, organizational transformation, and workflow optimization. As Vice President of Global Quality Assurance at LifeNet Health, Mr. Levermore leads the chart review process, performance improvement, postproduction releases, and strategic AI initiatives. Known for driving impactful change, he has delivered major efficiency gains, multimillion dollar savings, and award winning advancements in quality, innovation, and data visualization. In conjunction with LifeNet Health, Mr. Levermore provides sponsorship for data analytic practicums for multiple universities.

To receive emails on our upcoming programs, add reception@pharmaconference.com to your address book.

About the Speakers



Vivian C. Lopez, BS – Ms. Lopez is the QA Director for the Beauty of Sight Eye Bank, located at the Bascom Palmer Eye Institute in Miami, Florida. She has more than 30 years of experience in quality control operations, research and development, data analysis, equipment qualifications, process validations and establishing quality management systems. Ms. Lopez has worked in different FDA regulated industries such as Biotechnology, Diagnostics, Medical Device and in Eye Banking for the past 16 years.



Anna Greene McDonald, MD – Dr. McDonald has been the Medical Director at Birth Tissue Recovery since 2016. Her work is focused on determining donor eligibility to ensure tissue safety using her expertise in Perinatal and Forensic Pathology. Dr. McDonald is active in the AATB as Vice Chair of the Physician's Council, active in numerous working groups, and has authored numerous presentations regarding clinical relevance and tissue safety. She completed her medical degree at Duke University School of Medicine, Anatomic and Clinical Pathology residency at Massachusetts General Hospital, Pediatric Pathology fellowship at Boston Children's Hospital, and Forensic Pathology fellowship at the Boston OCME.



Owen Moore, BS – Mr. Moore brings more than five years of US and International Quality experience with a background in pharmaceutical excipients and cell therapies. A Senior Quality Liaison with NMDP, he works with the Quality Team, collaborating internally with cross-functional teams to ensure operations are conducted in compliance with all applicable regulations and standards. Mr. Moore also provides Quality support in an internal and external auditing capacity. Before working at NMDP, he worked as a Senior Quality Specialist at Hawkins Pharmaceuticals for manufacturing to ensure compliance for pharmaceutical excipient products.



Federico Rodriguez Quezada, BS, SBB, MLS (ASCP) – Mr. Quezada has over 36 years of experience in cellular therapy and immunohematology fields. He is currently the Client Services Manager with FACT CS. He earned his Bachelor of Science in Medical Technology from the Autonomous University of Nuevo Leon in Mexico; he graduated as Specialist in Blood Banking School at the University of Texas Medical Branch in Galveston, TX. Mr. Quezada's experience includes all aspects of manufacturing, regulatory requirements and compliance, process design, process improvement and quality management systems in the Cellular Therapy field, including BM, CB and PB as well as other novel therapies.



Carolyn Yong, MSE, PhD – Dr. Yong is a Vice President, Regulatory Affairs at MCRA, providing regulatory and compliance support to companies developing (361, 351) HCT/PS, regenerative medicine and combination products. She served at FDA for 11 years. Prior to joining MCRA, Dr. Yong was Chief of Special Projects and Policy Staff in the Office of Therapeutic Products and HCT/P regulatory framework expert in CBER. Additional former positions at FDA include Acting Cell Therapies Branch Chief, CMC Reviewer in CBER, and the Tissue Reference Group.



Jan Zajdowicz, BS, MS, CTBS – Mr. Zajdowicz is Vice President, Product Safety & Laboratory Services at AlloSource. He has worked 25+ years in various tissue banking functions, including microbiology, laboratory, quality, and research roles. Mr. Zajdowicz currently leads the product safety and quality laboratory teams at AlloSource, Centennial, CO. He volunteers for the American Association for Tissue Banks, serving as the committee chair for the Scientific and Technical Affairs Committee and leading subcommittees for emerging infectious diseases and Mycobacterium testing. Mr. Zajdowicz is a Certified Tissue Banking Specialist through AATB (2007-present).

To receive emails on our upcoming programs, add reception@pharmaconference.com to your address book.

Agenda



Continuing Education

This conference qualifies for 16.0 hours of continuing education credit.

Monday, April 13, 2026

Morning Session: Moderator – Alyce Linthurst Jones, PhD

8:00 – 9:00	Registration*	
9:00 – 9:10	Welcome*	
9:10 – 9:30	Personal Interest Story Related to HCT/Ps	To Be Introduced
9:30 – 10:15	FDA/DHT Update	Ping He, MD, FDA, CBER, OTP, OCTHT, DHT CONFIRMED
10:15 – 10:45	Compliance Update: The Stats – An Industry Perspective	Alyce Linthurst Jones, PhD
10:45 – 11:05	Break*	
11:05 – 11:50	Designing Machine Learning to Do Initial Donor Screening	Charles “Cheyne” Levermore
11:50 – 12:35	Regulatory GPS: Determining Your Product Classification and the Fastest Route to FDA Approval	Rebecca Brown, PhD
12:35 – 1:50	Lunch*	

Afternoon Session: Workshops

1:50 – 3:20	Workshop 1: Donor Eligibility & Screening Excellence: Strengthening Practices, Preventing Errors, and Preparing for FDA Audits This session offers practical guidance for strengthening donor eligibility workflows to meet FDA expectations and reduce compliance risks. Learn the most common documentation errors and proven strategies to prevent them, along with clear dos and don'ts, process improvements, and tools to enhance accuracy, consistency, and audit readiness.	<u>Moderator:</u> Wayne Dietz, CEBT <u>Speakers:</u> Wayne Dietz, CEBT Fatima Amchich Amy Johnson
-------------	---	---

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

Agenda



Continuing Education

This conference qualifies for 16.0 hours of continuing education credit.

Workshop 2: HCT/P Deviation Reporting

This workshop will look at logic used when determining the reportability of HCT/P deviations through case studies and interactive discussions. Different types of HCT/Ps will be covered, and audience participation is strongly encouraged.

Moderator: Erica Agy

Speakers:

Cell - Erica Agy

Ocular - Vivian Lopez

Tissue - Jonathan Boyd

3:20 – 3:40 Break*

3:40 – 5:10 **Workshops – above workshops repeat**

Tuesday, April 14, 2026

Morning Session: Moderator – Jennifer DeMatteo

9:00 – 9:05 Housekeeping Announcements*

9:05 – 10:05 **Microbiological Testing for Mtb (Mycobacterium) and rRNA Laboratory Developed Testing for Mtb in Surgical Site Infections Post-Allograft Implantation**

Jan Zajdowicz
Anna McDonald, MD

10:05 – 10:25 Break*

10:25 – 11:25 **A Novel HCT/P-Based Drug Product: Application, Regulatory Pathway, and Approach**

Katie Laney

11:25 – 12:25 **State of the Industry (including 15 minutes Q&A)**

Alexander Gaffney

12:25 – 1:40 Lunch*

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER



Afternoon Session: Workshops

1:40 – 3:10

WORKSHOPS SESSION 1

Repeats

Workshop 1: Lessons Learned and Considerations for Implementation and Execution of Electronic Batch Production Records, Including Demonstrations from an Electronic System

This workshop provides a high-level, regulator-aware overview of how artificial intelligence can be used responsibly in GxP-regulated environments. The session begins with AI literacy for regulated professionals, establishing a shared technical baseline without requiring a data science background. Participants will learn how modern AI systems function, including model behavior, context windows, and key limitations that directly impact risk, validation, and appropriate use. Building on that foundation, the workshop then addresses the regulatory, architectural, and data-handling considerations that govern AI deployment in GxP workflows. Rather than focusing on specific tools, the session emphasizes system design, intended use, governance, and oversight, aligning with FDA expectations. This workshop is a practical orientation to the concepts, constraints, and decisions that must be understood before AI can be introduced into regulated processes.

Chris Dayton

Repeats

Workshop 2: Tuberculosis and the Risk of Donor Derived Infection

This workshop will review the risk of tuberculosis (TB) transmission through organ and tissue transplantation, outline the biological and clinical pathways by which *Mycobacterium tuberculosis* can enter and propagate through the donation process, and evaluate current donor screening and diagnostic testing strategies.

Sally Alrabaa, MD

The talk will further examine documented cases and mechanisms of donor-derived TB transmission, highlight limitations of current screening approaches (history, imaging, TST/IGRA, microbiologic testing), and propose practical mitigation strategies for organ procurement organizations, tissue banks, and transplant programs, while preserving donor utilization.

Agenda



Continuing Education
This conference qualifies for 16.0
hours of continuing education credit.

One time

Workshop 3: Identifying a Standard Process for Implementing Commercially Available HCT/Ps within an Organization

Federico Rodriguez Quezada

This session outlines the end-to-end onboarding process for introducing novel cell therapies – e.g., CAR-T, genetically modified, etc. – into healthcare institutions, examines common operational, regulatory, and organizational challenges encountered before and during implementation, and identifies key stakeholders and their roles in ensuring a coordinated, efficient, and successful integration.

Objectives:

- Describe the general onboarding process to bring novel cell therapies into healthcare institutions.
- Discuss different challenges and roadblocks that institutions could face before and during the onboarding process.
- Identify key stakeholders and their roles that will make the process go seamlessly.

3:10 – 3:30

Break*

3:30 – 5:00

WORKSHOPS SESSION 2

Repeat

Workshop 1: Lessons Learned and Considerations for Implementation and Execution of Electronic Batch Production Records, Including Demonstrations from an Electronic System

Chris Dayton

This workshop provides a high-level, regulator-aware overview of how artificial intelligence can be used responsibly in GxP-regulated environments. The session begins with AI literacy for regulated professionals, establishing a shared technical baseline without requiring a data science background. Participants will learn how modern AI systems function, including model behavior, context windows, and key limitations that directly impact risk, validation, and appropriate use. Building on that foundation, the workshop then addresses the regulatory, architectural, and data-handling considerations that govern AI deployment in GxP workflows. Rather than focusing on specific tools, the session emphasizes system design, intended use, governance, and oversight, aligning with FDA expectations. This workshop is a practical orientation to the concepts, constraints, and decisions that must be understood before AI can be introduced into regulated processes.

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

Agenda



Continuing Education

This conference qualifies for 16.0 hours of continuing education credit.

Repeat

Workshop 2: Tuberculosis and the Risk of Donor Derived Infection

This workshop will review the risk of tuberculosis (TB) transmission through organ and tissue transplantation, outline the biological and clinical pathways by which *Mycobacterium tuberculosis* can enter and propagate through the donation process, and evaluate current donor screening and diagnostic testing strategies.

The talk will further examine documented cases and mechanisms of donor-derived TB transmission, highlight limitations of current screening approaches (history, imaging, TST/IGRA, microbiologic testing), and propose practical mitigation strategies for organ procurement organizations, tissue banks, and transplant programs, while preserving donor utilization.

Sally Alrabaa, MD

One time

Workshop 3: FDA Requirements for Reproductive HCT/Ps including Reproductive Donor Eligibility, Accompanying Records and Labeling Requirements with Case Scenarios

This workshop will serve as an interactive demonstration of the requirements of donor screening and testing, as well as how the results of donor screening and testing influence the content and applicability of the accompanying records and labeling for reproductive HCT/Ps using various scenarios.

Moderator: Sangita Jindal, PhD

Speakers:

Sangita Jindal, PhD

Amy Johnson

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

Agenda



Continuing Education

This conference qualifies for 16.0 hours of continuing education credit.

Wednesday, April 15, 2026

Morning Session: Moderator – Erica Agy

8:30 – 9:30	Warning Letters – Homologous Use in Advertising, Minimal Manipulation, and Sepsis: What Are These Telling Us About FDA's Current Thinking and Where is it Going?	Gail Javitt
9:30 – 10:30	HCT/Ps for Wounds: Regulatory Pathway Case Studies	Carolyn Yong, PhD
10:30 – 10:50	Break*	
10:50 – 11:25	Regulatory Jeopardy	Owen Moore
11:25 – 12:25	FDA OII Inspectional Process and Most Frequently Cited Observations	Laurissa Flowers, FDA, OII CONFIRMED
12:25 – 1:00	Ask the FDA	All FDA Speakers – invited

**Denotes Non-Educational Activity*

About the Venue

Perfectly positioned at the vibrant PenFed Plaza and directly connected to Tysons Corner Center Mall, the hotel offers unbeatable access to world-class shopping, dining and entertainment. Walk to hundreds of upscale boutiques and restaurants or hop on the Silver Line Metro, just steps away, for a quick 20-minute ride into the heart of Washington, D.C.

[CLICK HERE](#) for the website for our room block.

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

Registration

21ST ANNUAL

FDA AND THE CHANGING PARADIGM FOR HCT/P REGULATION

Fees

	<u>Industry</u>	<u>U.S. Gov't & Press</u>
SUPER EARLY 20% DISCOUNT: Payment Received By December 19, 2025	<input type="checkbox"/> \$1756	<input type="checkbox"/> \$1436
EARLY DISCOUNT: Payment Received December 20, 2025 – February 6, 2026	<input type="checkbox"/> \$2195	<input type="checkbox"/> \$1795
Payment Received After February 6, 2026	<input type="checkbox"/> \$2395	<input type="checkbox"/> \$1795

Includes conference materials, continental breakfasts, breaks, and lunches per agenda

Save with Group Discounts!

- 5 or more registrants from the same company registered & paid by 12/19/2025: 20% off the registration price*
- 5 to 9 registrants from the same company: 10% off the registration price*
- 10 or more registrants from the same company: 15% off the registration price*

* To receive the group discount, attendees must register on the group registration form and pay concurrently.

Cancellation Policy: 30 days or more for a full refund less \$250 USD cancellation fee per registrant; under 30 days, no refund, but attendee substitutions may be made at any time. Cancellations and substitutions must be made in writing to Pharma Conference (email registration@pharmaconference.com). In the event of any civil disorder, extremely adverse weather conditions, or other Acts of God, Pharma Conference reserves the right to reschedule the meeting dates in the interest of attendee safety.

Payment



- All credit card transactions are processed in US Dollars (your bank will convert to your local exchange rate when billing)
- You will receive a confirmation via email as soon as the registration is processed. In order to receive any early registration discounts, payment must be made by the deadline specified in the brochure. (Taxpayer ID #27-1438344)
- Registrations must be accompanied by full payment.

Payment Terms: Conference attendees must be paid in full prior to conference start date.

CLICK HERE TO REGISTER NOW ON OUR SECURE SERVER

Hotel

Hyatt Regency Tysons Corner Center

7901 Tysons One Place | Tysons Corner, Virginia 22102 | (703) 893-1234

\$299 single/double

A limited number of rooms have been blocked at the special rate listed per night. Rate is based on single or double occupancy. Rate is available 3 nights either side of the conference dates based upon availability of rooms. **Hotel reservations must be made on or before March 23, 2026, in order to guarantee the special rate.** Individuals are responsible for making their own hotel reservations. **If calling, you must mention you are with the group, 21st Annual FDA & Changing Paradigm for HCT/P Regulation, when making your reservation in order to obtain these special rates. Please do not use travel agents for reservations.**

Reservations:
(703) 893-1234 or (877) 803-7534

Online reservations:
21st Annual HCT/P

If page does not open, copy and paste this URL in your browser to make hotel reservations online: <https://www.hyatt.com/events/en-US/group-booking/IADRT/G-PHAR>

For additional information, contact Pharma Conference Inc: (830) 315-0055 • e-mail: contactus@pharmaconference.com